Literature DB >> 25557032

Active components alignment of Gegenqinlian decoction protects ulcerative colitis by attenuating inflammatory and oxidative stress.

Bei-Lei Xu1, Gui-Jun Zhang2, Yu-Bin Ji3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Gegenqinlian Decoction (GQD) has been used as a folk remedy for gastrointestinal diseases in China over thousands of years. It has significant treatment efficacy for patients with inflammatory bowel disease (IBD). We analyzed and showed that the active components alignment of Gegenqinlian Decoction (ACAG) possesses broad pharmacological effects including analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral and antidiarrhea, as well as the effect of adjusting gastrointestinal function in our preliminary experiments. However, the exact molecular mechanisms on how ACAG exerts these pharmacological effects still remain elusive. In the present study, the plausible pharmacological effects of ACAG on 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis were investigated.
MATERIALS AND METHODS: Male Sprague-Dawley (SD) rats with TNBS/ethanol-induced colitis were used. The colonic wet weight, macroscopic and histological colon injury, superoxide dismutase (SOD), malonyldialdehyde (MDA), and inducible nitric oxide synthase (iNOS) activity were observed. Pro-inflammation cytokines were determined by ELISA methods, semi-quantitative RT-PCR and Immuno-histochemistry.
RESULTS: We showed administration of ACAG was able to improve colitis. This was manifested by a decreased in the score of macroscopic and histological colonic injury, by lowered colonic wet weight, accompanied by significant increased of SOD activity, and decreased of MDA and iNOS activities. The treatment also significantly reduced tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) levels in colon and serum as well as the colonic mRNA levels for several inflammatory cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), macrophage inflammatory protein-2 (MIP-2), intercellular adhesion molecule-1 (ICAM-1) and toll-like receptor 2, 4 (TLR2, TLR4). In addition, we also showed that ACAG was able to inhibit the activation and translocation of transcription factors, nuclear factor kappaBp65 (NF-κBp65) in colon.
CONCLUSIONS: Our results suggest that ACAG exhibits protective effect in TNBS-induced ulcerative colitis. We postulate that this might be due to its modulation of oxidant/anti-oxidant balance, downregulation of productions, expressions of pro-inflammatory cytokines and inhibition of NF-κBp65 signal transduction pathways.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Active components alignment of Gegenqinlian Decoction (ACAG); ELISA; Immuno-histochemistry; Nuclear factor-kappa B; Semi-quantitative RT-PCR; TNBS-induced colitis

Mesh:

Substances:

Year:  2014        PMID: 25557032     DOI: 10.1016/j.jep.2014.12.042

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  16 in total

1.  Animal Models and Pathogenesis of Ulcerative Colitis.

Authors:  Xin Gao; Jia Li; Xueping Pang; Kaiyuan Cong; Chunlei Jiang; Bingxuan Han; Jiawei Gao; Zhihao Wang; Jiangshan Hu; Kaijun Wen; Xinfa Ye; Liwen Dou
Journal:  Comput Math Methods Med       Date:  2022-07-11       Impact factor: 2.809

2.  Sijunzi Decoction attenuates 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced claudin-2 damage via NF-κB pathway in Caco2 cells.

Authors:  Yue Lu; HanJie Lin; JinWei Zhang; JianAn Wei; Jing Sun; Ling Han
Journal:  BMC Complement Altern Med       Date:  2017-01-10       Impact factor: 3.659

3.  Protective Effect of Methane-Rich Saline on Acetic Acid-Induced Ulcerative Colitis via Blocking the TLR4/NF-κB/MAPK Pathway and Promoting IL-10/JAK1/STAT3-Mediated Anti-inflammatory Response.

Authors:  Guanghui Wang; Bing Xu; Feiyu Shi; Mengfan Du; Yaguang Li; Tianyu Yu; Lihong Chen
Journal:  Oxid Med Cell Longev       Date:  2019-04-28       Impact factor: 6.543

Review 4.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

5.  Efficacy of herbal medicine (Gegen Qinlian Decoction) on ulcerative colitis: A systematic review of randomized controlled trials.

Authors:  Yuling Fan; Wen Yi; Han Huang; Zhigang Mei; Zhitao Feng
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

6.  In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis.

Authors:  Xiaolu Liu; Yuling Fan; Lipeng Du; Zhigang Mei; Yang Fu
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

Review 7.  Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?

Authors:  Fabiana Andréa Moura; Kívia Queiroz de Andrade; Juliana Célia Farias Dos Santos; Orlando Roberto Pimentel Araújo; Marília Oliveira Fonseca Goulart
Journal:  Redox Biol       Date:  2015-10-23       Impact factor: 11.799

8.  Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats.

Authors:  Gulserap Yildiz; Yuksel Yildiz; Pinar A Ulutas; Asl Yaylali; Muruvvet Ural
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2015

9.  Gegen Qinlian Decoction Treats Diarrhea in Piglets by Modulating Gut Microbiota and Short-Chain Fatty Acids.

Authors:  Chang-Shun Liu; Xiao Liang; Xiao-Han Wei; Zhen Jin; Fei-Long Chen; Qing-Fa Tang; Xiao-Mei Tan
Journal:  Front Microbiol       Date:  2019-04-18       Impact factor: 5.640

Review 10.  Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways.

Authors:  Aida Kamalian; Masoud Sohrabi Asl; Mahsa Dolatshahi; Khashayar Afshari; Shiva Shamshiri; Nazanin Momeni Roudsari; Saeideh Momtaz; Roja Rahimi; Mohammad Abdollahi; Amir Hossein Abdolghaffari
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.